Terminated PHASE4 INTERVENTIONAL 2-arm NCT00488059

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (AMICI)

A Multicenter, Open-label Study Evaluating the Antiviral Activity and Safety of Enfuvirtide (ENF) Once Daily (QD) or Twice Daily (BID) in Triple-class Experienced HIV-1 Infected Patients Changing Their Therapy to a Standard of Care (SOC) Regimen That Includes Initiating Raltegravir Plus an Optimized Background (OB) Antiviral Regimen

Sponsor: Hoffmann-La Roche

Conditions HIV Infections

Interventions Integrase inhibitor Optimized background ARV enfuvirtide [Fuzeon]

Updated 9 times since 2017 Last updated: Jul 18, 2011 Started: Jun 30, 2007 Primary completion: Oct 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated early due to poor enrollment.

Other terminated trials from Hoffmann-La Roche

See all terminations from Hoffmann-La Roche

Other HIV Infections trials with similar outcome

Browse all HIV Infections trials

A PHASE4 clinical study on HIV Infections, this trial is terminated or withdrawn. The trial is conducted by Hoffmann-La Roche and has accumulated 9 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE4
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE4
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE4

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE4
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE4

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche
Trimeris

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Annandale, United States , Atlanta, United States , Boston, United States , Briarcliff Manor, United States , Chicago, United States , Dallas, United States , Fort Lauderdale, United States , Fort Myers, United States , Fort Worth, United States and 28 more locations